Heavy smoking, reduced olanzapine levels, and treatment effects - A case report

被引:13
作者
Chiu, CC
Lu, ML
Huang, MC
Chen, KP
机构
[1] Taipei City Psychiat Ctr, Lab Biol Psychiat, Taipei, Taiwan
[2] Taipei Med Univ, Grad Inst Nutr & Hlth Sci, Taipei, Taiwan
[3] Taipei Med Univ, Wan Fang Hosp, Dept Psychiat, Taipei, Taiwan
关键词
olanzapine; therapeutic drug monitoring; smoking; cytochrome P450;
D O I
10.1097/00007691-200410000-00018
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
A 30-year-old schizophrenic male patient, a heavy smoker, was successfully treated with olanzapine 15 mg/d during hospitalization. His cigarette consumption increased rapidly from 12 to 80 cigarettes per day following his discharge. Ten days later, his delusion of persecution, levels of hostility, and aggressive behavior worsened, while the plasma levels of olanzapine concurrently decreased. Based on our observations of this case, we suggest that the reduced levels of plasma olanzapine and exacerbated clinical symptoms are closely related to the increased consumption of cigarettes. A possible explanation would be that heavy smoking induced cytochrome P4501A2, the major enzyme involved in olanzapine metabolism. Therefore, patients who smoke should be closely monitored for their cigarette consumption when the dosage of olanzapine is adjusted.
引用
收藏
页码:579 / 581
页数:3
相关论文
共 16 条
[1]   IMPAIRMENT OF CAFFEINE CLEARANCE BY CHRONIC USE OF LOW-DOSE ESTROGEN-CONTAINING ORAL-CONTRACEPTIVES [J].
ABERNETHY, DR ;
TODD, EL .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1985, 28 (04) :425-428
[2]   Role of the smoking-induced cytochrome P450 (CYP)1A2 and polymorphic CYP2D6 in steady-state concentration of olanzapine [J].
Carrillo, JA ;
Herráiz, AG ;
Ramos, SI ;
Gervasini, G ;
Vizcaíno, S ;
Benítez, J .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2003, 23 (02) :119-127
[3]   Olanzapine - A review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses [J].
Fulton, B ;
Goa, KL .
DRUGS, 1997, 53 (02) :281-298
[4]   Therapeutic drug monitoring of olanzapine: The combined effect of age, gender, smoking, and comedication [J].
Gex-Fabry, M ;
Balant-Gorgia, AE ;
Balant, LP .
THERAPEUTIC DRUG MONITORING, 2003, 25 (01) :46-53
[5]  
Jefferson JW, 1998, J CLIN PSYCHIAT, V59, P37
[6]   CAFFEINE AS A METABOLIC PROBE - EXPLORATION OF THE ENZYME-INDUCING EFFECT OF CIGARETTE-SMOKING [J].
KALOW, W ;
TANG, BK .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1991, 49 (01) :44-48
[7]  
Kelly C, 1999, AM J PSYCHIAT, V156, P1751
[8]  
MASUBUCHI Y, 1994, DRUG METAB DISPOS, V22, P909
[9]   Individual changes in clozapine levels after smoking cessation: Results and a predictive model [J].
Meyer, JM .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2001, 21 (06) :569-574
[10]   Olanzapine plasma concentrations and clinical response: Acute phase results of the North American Olanzapine Trial [J].
Perry, PJ ;
Lund, BC ;
Sanger, T ;
Besley, C .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2001, 21 (01) :14-20